Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Free Cash Flow for 9 consecutive years, with -$66.6 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 23.38% year-over-year to -$66.6 million; the TTM value through Mar 2026 reached -$231.7 million, down 27.27%, while the annual FY2025 figure was -$252.0 million, 51.86% down from the prior year.
  • Free Cash Flow hit -$66.6 million in Q1 2026 for Bicycle Therapeutics, down from -$19.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $33.8 million in Q2 2023 and bottomed at -$87.0 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$38.4 million, with a median of -$40.3 million recorded in 2024.
  • Year-over-year, Free Cash Flow skyrocketed 201.47% in 2023 and then tumbled 2537.0% in 2024.
  • Bicycle Therapeutics' Free Cash Flow stood at -$31.8 million in 2022, then plummeted by 49.07% to -$47.3 million in 2023, then soared by 79.37% to -$9.8 million in 2024, then tumbled by 104.01% to -$19.9 million in 2025, then plummeted by 234.53% to -$66.6 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$66.6 million, -$19.9 million, and -$71.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.